Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AG-181

Small molecule · developed by Agios Pharmaceuticals

Phase 1 Most advanced trial

AGIO Developer

1 Registered trials

What is AG-181?

AG-181 is an investigational small-molecule drug studied in Phenylketonuria.

At a glance

Drug type: Small molecule
Therapy area: Neurology
Developer: Agios Pharmaceuticals, Inc. (AGIO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07241234	Phase 1	Phenylketonuria	Recruiting	AGIO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Phenylketonuria

More from Agios Pharmaceuticals

Mitapivat FDA approved AG-236 Phase 2/3 AG-636 Phase 1 AG-881 Phase 1 Tebapivat Phase 2

Sources

ClinicalTrials.gov NCT07241234

Updated Oct 3, 2026. Something wrong or missing? Report it on the AGIO page.

Follow AGIO, the company behind AG-181

See AGIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AGIO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z